NASDAQ:LNSR LENSAR (LNSR) Stock Price, News & Analysis $8.68 +0.24 (+2.84%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About LENSAR Stock (NASDAQ:LNSR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENSAR alerts:Sign Up Key Stats Today's Range$8.42▼$8.7050-Day Range$5.01▼$8.7252-Week Range$4.95▼$12.96Volume167,286 shsAverage Volume194,485 shsMarket Capitalization$106.68 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingHold Company Overview LENSAR, Inc., headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions. Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. The company holds multiple patents related to its image-guided treatment planning and laser control algorithms. Clinical collaborations and peer-reviewed studies have supported the safety and efficacy of the LENSAR system, demonstrating improvements in procedural consistency and efficiency. Operating across North America, Europe, the Asia-Pacific region and Latin America, LENSAR markets its laser platforms to hospitals, ambulatory surgery centers and specialty eye clinics. The company offers comprehensive training programs for ophthalmic surgeons, ongoing technical support and regular software upgrades to help practices integrate femtosecond laser technology. By maintaining a focused portfolio of ophthalmic solutions, LENSAR seeks to advance the standard of care in cataract surgery through continuous innovation and service excellence.AI Generated. May Contain Errors. Read More LENSAR Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreLNSR MarketRank™: LENSAR scored higher than 47% of companies evaluated by MarketBeat, and ranked 542nd out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingLENSAR has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLENSAR has a consensus price target of $11.50, representing about 32.5% upside from its current price of $8.68.Amount of Analyst CoverageLENSAR has only been the subject of 3 research reports in the past 90 days.Read more about LENSAR's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -26.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -26.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENSAR has a P/B Ratio of 7.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.74% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 12.17, which indicates bearish sentiment.Change versus previous monthShort interest in LENSAR has recently decreased by 6.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.55 News SentimentLENSAR has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for LENSAR this week, compared to 1 article on an average week.Search Interest1 people have searched for LNSR on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders65.80% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENSAR's insider trading history. Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNSR Stock News HeadlinesBTIG Research Raises LENSAR (NASDAQ:LNSR) Price Target to $10.0020 minutes ago | americanbankingnews.comLENSAR (NASDAQ:LNSR) Price Target Raised to $9.00August 16, 2026 | americanbankingnews.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before August 31, pointing to a critical shift ahead for tech and AI-related stocks. | TradeSmith (Ad)Wall Street Zen Upgrades LENSAR (NASDAQ:LNSR) to "Hold"August 15, 2026 | americanbankingnews.comLENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability SurgeAugust 13, 2026 | uk.finance.yahoo.comLENSAR IncAugust 13, 2026 | edition.cnn.comLENSAR signals opex to rise modestly as ALLY backlog reaches 13 systemsAugust 13, 2026 | seekingalpha.comLENSAR, Inc. (LNSR) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | seekingalpha.comSee More Headlines LNSR Stock Analysis - Frequently Asked Questions How have LNSR shares performed this year? LENSAR's stock was trading at $11.63 at the beginning of the year. Since then, LNSR stock has decreased by 25.4% and is now trading at $8.68. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) issued its quarterly earnings data on Thursday, August, 13th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.27. The firm earned $16.50 million during the quarter, compared to analyst estimates of $14.65 million. LENSAR had a net margin of 57.57% and a negative trailing twelve-month return on equity of 529.08%. Read the conference call transcript. Who are LENSAR's major shareholders? Top institutional investors of LENSAR include BlackRock Inc. (1.51%), DCF Advisers LLC (0.96%), Man Group plc (0.63%) and Susquehanna International Group LLP (0.36%). View institutional ownership trends. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENSAR own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), Baidu (BIDU), Cidara Therapeutics (CDTX) and Carlyle Group (CG). Company Calendar Last Earnings8/13/2026Today8/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 9 days, LNSR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:LNSR CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for LENSAR$11.50 High Price Target$13.00 Low Price Target$10.00 Potential Upside/Downside+32.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.28 million Net Margins57.57% Pretax Margin57.57% Return on Equity-529.08% Return on Assets50.03% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio1.13 Sales & Book Value Annual Sales$58.44 million Price / Sales1.83 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book7.17Miscellaneous Outstanding Shares12,290,000Free Float4,202,000Market Cap$106.68 million OptionableOptionable Beta0.89 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:LNSR) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe world's #2 gold miner is running on fumes [it has to buy]Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.